10 Worst ARK Stocks To Buy According To Short Sellers
Investing comes in all sizes and flavors. For the risk averse investors that are looking for steady payouts or long term stability, value and dividend paying stocks are the way to go.
Arcturus Therapeutics Holdings Inc. (ARCT)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | ARK Investment Management Catherine D. Wood | 1,964,964 | $47,846,871 | +17% | 0.42% |
| 2. | Woodline Partners Michael Rockefeller And Karl Kroeker | 754,023 | $18,360,460 | -18% | 0.17% |
| 3. | Millennium Management Israel Englander | 555,024 | $13,514,834 | +251% | 0% |
| 4. | Portolan Capital Management George Mccabe | 484,907 | $11,807,485 | +99% | 0.97% |
| 5. | Schonfeld Strategic Advisors Ryan Tolkin (Cio) | 283,420 | $6,901,275 | -19% | 0.04% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $18.00 | 2,222 | Director | 24,942 | 2022-12-15 | Filing | |
| $16.51 | 5,000 | Officer, Director | 1,480,097 | 2022-11-23 | Filing | |
| $33.33 | 450 | Officer | 950 | 2020-06-12 | Filing | |
| $31.69 | 1,000 | Officer, Director | 1,475,097 | 2020-06-10 | Filing | |
| $29.74 | 5,000 | Officer, Director | 273,245 | 2020-06-10 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $32.03 | 50,000 | Officer, Director | 220,526 | 2024-06-12 | Filing | |
| $45.00 | 114 | Officer | 447,334 | 2024-06-05 | Filing | |
| $40.01 | 26,000 | Officer | 447,448 | 2024-06-03 | Filing | |
| $35.02 | 17,435 | Officer | 473,448 | 2024-03-25 | Filing | |
| $35.01 | 8,565 | Officer | 490,883 | 2024-03-19 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 4,711,512 | $148,553,973 | 0.36% | |
| 2. | 2,398,296 | $75,618,272 | 0% | |
| 3. | 1,629,666 | $51,383,369 | 0% | |
| 4. | 1,458,380 | $45,982,722 | 0% | |
| 5. | 1,320,652 | $41,640,158 | 0.03% |
News See All
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q2 2024 Earnings Call Transcript
Operator: Greetings and welcome to Arcturus Therapeutics' Second Quarter 2024 Earnings Call. At this time, all participants are in a listen-only mode.
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q1 2024 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen, and welcome to the Arcturus Therapeutics First Quarter 2024 Earnings Call. At this time, all lines are in listen-only mode.
12 Most Undervalued Biotech Stocks To Buy According To Hedge Funds
In this article, we discuss 12 most undervalued biotech stocks to buy according to hedge funds.
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q4 2023 Earnings Call Transcript
Arcturus Therapeutics Holdings Inc. beats earnings expectations. Reported EPS is $-0.32, expectations were $-1.69.
18 High Growth Low PE Stocks
When value stocks came back with a vengeance in 2022, value investors cheered what they thought was the beginning of a long bull run of value stocks.
12 Best Healthcare Stocks For the Long-Term
In this piece, we will take a look at the 12 best healthcare stocks for the long term.
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q3 2023 Earnings Call Transcript
Operator: Greetings and welcome to the Arcturus Therapeutics Third Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode.
5 Most Undervalued Biotech Stocks to Buy According to Analysts
In this article, we will take a look at the 5 most undervalued biotech stocks to buy according to analysts.
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q2 2023 Earnings Call Transcript
Operator: Greetings, and welcome to Arcturus Therapeutics Second Quarter 2023 Earnings Call. At this time, all participants are in a listen-only mode.